Alexion Pharma to lay off 20 percent of workforce

Alexion Pharma (ALXN) Announces Interim Analysis from Phase 3 Open-Label Extension Study Shows Sustained Benefits of Soliris (Eculizumab) Treatment

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris® (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The new results show sustained treatment benefits across a range of MG-specific assessment scales through an additional 52 weeks for patients who continued to receive Soliris, and also demonstrate rapid, significant and sustained improvements through 52 weeks for patients who had crossed over from placebo in REGAIN to Soliris treatment in... More

Biogen (BIIB) PT Raised to $377 at BMO Capital Following 'Deep Dive on Aducanumab, More Confident on Phase 3 Outcome'

BMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $377.00 (from $328.00) while maintaining a Market Perform rating, following a review of aducanumab.

Analyst M. Ian Somaiya notes a positive outlook follow a detailed review of aducanumab, suggesting the analysis points to... More

Alexion Pharmaceuticals (ALXN) PT Raised to $158 at Deutsche Bank Following Restructuring News

Deutsche Bank raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $158.00 (from $153.00) while maintaining a Buy rating following the company's restructuring announcement.

Analyst... More

Alexion Pharmaceuticals (ALXN) PT Raised to $173 at BMO Capital

BMO Capital analyst M. Ian Somaiya raised his price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $173.00 (from $168.00) while maintaining a Outperform rating as the company's plan to cut 20% of its workforce leading to $250mn annual savings was foreshadowed by prior guidance of non-GAAP operating... More